FDA unveils new pathway to usher bespoke therapies to market
The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases.
Cytiva Navigating cell therapy WP 4
Lyell acquires worldwide rights from ICT to CAR T-cell therapy
Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal
FDA halts uniQure’s plans for Huntington’s disease gene therapy
Helex secures $3.5m to advance kidney disease therapies
Eli Lilly buys Adverum in eye disease gene therapy punt
Galapagos to shutter cell and gene therapy unit
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
